Advisory Services Network’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.68M | Buy |
4,289
+336
| +8% | +$229K | 0.03% | 588 |
|
|
2026
Q1 | $3.05M | Buy |
3,953
+65
| +2% | +$49.8K | 0.04% | 479 |
|
|
2025
Q4 | $3M | Sell |
3,888
-93
| -2% | -$63.2K | 0.04% | 463 |
|
|
2025
Q3 | $2.24M | Sell |
3,981
-49
| -1% | -$27.7K | 0.03% | 546 |
|
|
2025
Q2 | $2.2M | Sell |
4,030
-1,845
| -31% | -$1.03M | 0.04% | 523 |
|
|
2025
Q1 | $3.73M | Buy |
5,875
+953
| +19% | +$655K | 0.07% | 313 |
|
|
2024
Q4 | $3.51M | Buy |
4,922
+129
| +3% | +$108K | 0.07% | 328 |
|
|
2024
Q3 | $5.04M | Hold |
4,793
| – | – | 0.1% | 205 |
|
|
2024
Q2 | $5.04M | Buy |
4,793
+205
| +4% | +$199K | 0.1% | 205 |
|
|
2024
Q1 | $4.42M | Sell |
4,588
-106
| -2% | -$101K | 0.1% | 231 |
|
|
2023
Q4 | $4.12M | Buy |
4,694
+298
| +7% | +$245K | 0.1% | 230 |
|
|
2023
Q3 | $3.62M | Buy |
4,396
+95
| +2% | +$74.7K | 0.1% | 240 |
|
|
2023
Q2 | $3.09M | Buy |
4,301
+154
| +4% | +$119K | 0.08% | 287 |
|
|
2023
Q1 | $3.41M | Sell |
4,147
-205
| -5% | -$155K | 0.09% | 254 |
|
|
2022
Q4 | $3.14M | Sell |
4,352
-157
| -3% | -$116K | 0.1% | 250 |
|
|
2022
Q3 | $3.11M | Sell |
4,509
-64
| -1% | -$40.3K | 0.11% | 228 |
|
|
2022
Q2 | $2.7M | Sell |
4,573
-308
| -6% | -$200K | 0.09% | 260 |
|
|
2022
Q1 | $3.41M | Sell |
4,881
-428
| -8% | -$271K | 0.1% | 239 |
|
|
2021
Q4 | $3.35M | Sell |
5,309
-1,097
| -17% | -$674K | 0.1% | 260 |
|
|
2021
Q3 | $3.88M | Buy |
6,406
+1,507
| +31% | +$936K | 0.12% | 207 |
|
|
2021
Q2 | $2.74M | Buy |
4,899
+3,175
| +184% | +$1.61M | 0.09% | 298 |
|
|
2021
Q1 | $816K | Sell |
1,724
-843
| -33% | -$410K | 0.03% | 628 |
|
|
2020
Q4 | $1.24M | Buy |
2,567
+445
| +21% | +$240K | 0.05% | 429 |
|
|
2020
Q3 | $1.19M | Sell |
2,122
-1,998
| -48% | -$1.21M | 0.06% | 368 |
|
|
2020
Q2 | $2.57M | Buy |
4,120
+1,930
| +88% | +$1.1M | 0.14% | 184 |
|
|
2020
Q1 | $1.07M | Buy |
2,190
+1,465
| +202% | +$604K | 0.07% | 318 |
|
|
2019
Q4 | $273K | Sell |
725
-175
| -19% | -$58.9K | 0.01% | 815 |
|
|
2019
Q3 | $282K | Hold |
900
| – | – | 0.02% | 720 |
|
|
2019
Q2 | $282K | Sell |
900
-3,507
| -80% | -$1.17M | 0.02% | 718 |
|
|
2019
Q1 | $1.81M | Buy |
4,407
+3,513
| +393% | +$1.45M | 0.13% | 206 |
|
|
2018
Q4 | $333K | Buy |
894
+231
| +35% | +$84.5K | 0.03% | 559 |
|
|
2018
Q3 | $267K | Hold |
663
| – | – | 0.02% | 683 |
|
|
2018
Q2 | $248K | Buy |
663
+277
| +72% | +$86.6K | 0.02% | 686 |
|
|
2018
Q1 | $133K | Sell |
386
-61
| -14% | -$21.2K | 0.01% | 919 |
|
|
2017
Q4 | $168K | Buy |
447
+266
| +147% | +$108K | 0.01% | 834 |
|
|
2017
Q3 | $81K | Buy |
181
+132
| +269% | +$62.8K | 0.01% | 929 |
|
|
2017
Q2 | $24K | Buy |
49
+9
| +23% | +$3.94K | ﹤0.01% | 1291 |
|
|
2017
Q1 | $16K | Buy |
+40
| New | +$14.8K | ﹤0.01% | 1315 |
|
|
2016
Q3 | $241K | Buy |
600
+268
| +81% | +$108K | 0.05% | 456 |
|
|
2016
Q2 | $116K | Buy |
332
+326
| +5,433% | +$126K | 0.03% | 575 |
|
|
2016
Q1 | $2K | Buy |
+6
| New | +$2.47K | ﹤0.01% | 1503 |
|
|
2015
Q3 | – | Sell |
-1
| Closed | -$1K | – | 1579 |
|
|
2015
Q2 | $1K | Sell |
1
-14
| -93% | -$6.83K | ﹤0.01% | 1353 |
|
|
2015
Q1 | $7K | Sell |
15
-7
| -32% | -$2.97K | ﹤0.01% | 916 |
|
|
2014
Q4 | $9K | Buy |
+22
| New | +$8.65K | ﹤0.01% | 766 |
|
|
2014
Q1 | – | Sell |
-28
| Closed | -$8K | – | 670 |
|
|
2013
Q4 | $8K | Buy |
+28
| New | +$8.05K | ﹤0.01% | 667 |
|
Other funds holding REGN
Advisory Services Network's REGN Position: Q2 2026 in Review
Advisory Services Network increased its Regeneron Pharmaceuticals (REGN) stake by 8.5% in Q2 2026, buying an estimated $229K and bringing the position to 4,289 shares worth $2.68M. The position accounts for 0.03% of the portfolio, ranked #588.
Advisory Services Network first reported a position in REGN in Q4 2013 and has held it in 45 quarters since. The position peaked at $5.04M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Advisory Services Network held 4,289 shares of Regeneron Pharmaceuticals worth $2.68M as of Q2 2026.
- Advisory Services Network bought 336 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $229K.
- Regeneron Pharmaceuticals made up 0.03% of Advisory Services Network's portfolio in Q2 2026, its #588 holding.
- Advisory Services Network first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 45 quarters since.
- Advisory Services Network's Regeneron Pharmaceuticals position peaked at $5.04M in Q3 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.